請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29728完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林慧玲(Fe-Lin Lin) | |
| dc.contributor.author | Ming-Tang Yang | en |
| dc.contributor.author | 楊明唐 | zh_TW |
| dc.date.accessioned | 2021-06-13T01:16:28Z | - |
| dc.date.available | 2012-08-16 | |
| dc.date.copyright | 2007-08-16 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-07-19 | |
| dc.identifier.citation | Abt, A. B., J. Y. Oh, et al. (1995). 'Chinese herbal medicine induced acute renal failure.' Arch Intern Med 155(2): 211-2.
Arlt, V. M., A. Pfohl-Leszkowicz, et al. (2001). 'Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy.' Mutat Res 494(1-2): 143-50. Arlt, V. M., M. Stiborova, et al. (2002). 'Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.' Mutagenesis 17(4): 265-77. Balachandran, P., F. Wei, et al. (2005). 'Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells.' Kidney Int 67(5): 1797-805. Bell, D. R., J. M. Trent, et al. (1987). 'Chromosomal location of human P-glycoprotein gene sequences.' Cancer Genet Cytogenet 25(1): 141-8. Bieler, C. A., M. Stiborova, et al. (1997). '32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy.' Carcinogenesis 18(5): 1063-7. Briggs, J. D., F. Berthoux, et al. (2000). 'Predictions for future growth of ESRD prevalence.' Kidney International 57: S46–S48. Burczynski, M. E. and T. M. Penning (2000). 'Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor.' Cancer Res 60(4): 908-15. Chae, Y. H., K. B. Delclos, et al. (1996). 'Metabolism and DNA binding of the environmental colon carcinogen 6-nitrochrysene in rats.' Cancer Res 56(9): 2052-8. Chang, C. H., Y. M. Wang, et al. (2001). 'Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications.' Am J Nephrol 21(6): 441-8. Chen, C. L., Q. Liu, et al. (1996). 'Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks.' Pharmacogenetics 6(2): 187-91. Chen, W., Y. Chen, et al. (2001). '[The clinical and pathological manifestations of aristolochic acid nephropathy--the report of 58 cases].' Zhonghua Yi Xue Za Zhi 81(18): 1101-5. Chen, X., H. Wang, et al. (2006). 'Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China.' Pharmacogenet Genomics 16(3): 219-227. Chen, X., L. Wang, et al. (2005). 'The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population.' Clin Pharmacol Ther 78(3): 249-59. Cheng, C. L., K. J. Chen, et al. (2006). 'Chronic renal failure rats are highly sensitive to aristolochic acids, which are nephrotoxic and carcinogenic agents.' Cancer Lett 232(2): 236-42. Cheng, Y. J., Y. C. Chien, et al. (2003). 'No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2, and nasopharyngeal carcinoma in Taiwan.' Cancer Epidemiol Biomarkers Prev 12(2): 179-80. Cheung, Y. L., A. C. Kerr, et al. (1999). 'Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours.' Cancer Lett 139(2): 199-205. Corchero, J., S. Pimprale, et al. (2001). 'Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation.' Pharmacogenetics 11(1): 1-6. Cosyns, J. P., J. P. Dehoux, et al. (2001). 'Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy?' Kidney Int 59(6): 2164-73. Cosyns, J. P., M. Jadoul, et al. (1999). 'Urothelial lesions in Chinese-herb nephropathy.' Am J Kidney Dis 33(6): 1011-7. Debelle, F. D., J. L. Nortier, et al. (2002). 'Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats.' J Am Soc Nephrol 13(2): 431-6. Deitz, A. C., M. A. Doll, et al. (1997). 'A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles.' Anal Biochem 253(2): 219-24. Drew, A. K. and S. P. Myers (1997). 'Safety issues in herbal medicine: implications for the health professions.' Med J Aust 166(10): 538-41. Eichelbaum, M., M. F. Fromm, et al. (2004). 'Clinical aspects of the MDR1 (ABCB1) gene polymorphism.' Ther Drug Monit 26(2): 180-5. Ernst, E. (2003). 'Serious adverse effects of unconventional therapies for children and adolescents: a systematic review of recent evidence.' Eur J Pediatr 162(2): 72-80. Foundation, N. K. (2005). '2005 statistics data about amount of dialysis patients in Taiwan.' from http://www.kidney.org.tw/. Frei, H., F. E. Wurgler, et al. (1985). 'Aristolochic acid is mutagenic and recombinogenic in Drosophila genotoxicity tests.' Arch Toxicol 56(3): 158-66. Garrick, R. A., B. R. Woodin, et al. (2006). 'Cytochrome P4501A is induced in endothelial cell lines from the kidney and lung of the bottlenose dolphin, Tursiops truncatus.' Aquat Toxicol 76(3-4): 295-305. Geick, A., M. Eichelbaum, et al. (2001). 'Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin.' J Biol Chem 276(18): 14581-7. Georgiadis, P., J. Topinka, et al. (2005). 'Interactions between CYP1A1 polymorphisms and exposure to environmental tobacco smoke in the modulation of lymphocyte bulky DNA adducts and chromosomal aberrations.' Carcinogenesis 26(1): 93-101. Gillerot, G., M. Jadoul, et al. (2001). 'Aristolochic acid nephropathy in a Chinese patient: time to abandon the term 'Chinese herbs nephropathy'?' Am J Kidney Dis 38(5): E26. Goto, M., S. Masuda, et al. (2002). 'C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.' Pharmacogenetics 12(6): 451-7. Gotzl, E. and O. Schimmer (1993). 'Mutagenicity of aristolochic acids (I, II) and aristolic acid I in new YG strains in Salmonella typhimurium highly sensitive to certain mutagenic nitroarenes.' Mutagenesis 8(1): 17-22. Guengerich, F. P. (1993). 'The 1992 Bernard B. Brodie Award Lecture. Bioactivation and detoxication of toxic and carcinogenic chemicals.' Drug Metab Dispos 21(1): 1-6. Hauser, I. A., E. Schaeffeler, et al. (2005). 'ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.' J Am Soc Nephrol 16(5): 1501-11. Hayashi, S., J. Watanabe, et al. (1991). 'Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene.' J Biochem (Tokyo) 110(3): 407-11. Hein, D. W., D. M. Grant, et al. (2000). 'Update on consensus arylamine N-acetyltransferase gene nomenclature.' Pharmacogenetics 10(4): 291-2. Hoffmeyer, S., O. Burk, et al. (2000). 'Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.' Proc Natl Acad Sci U S A 97(7): 3473-8. Hsieh, F. I., Y. S. Pu, et al. (1999). 'Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.' Br J Cancer 81(3): 537-41. Hsin, Y. H., C. H. Cheng, et al. (2006). 'Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells.' Apoptosis 11(12): 2167-77. Huang, C. S., H. D. Chern, et al. (1999). 'Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence.' Int J Cancer 82(2): 175-9. Huang, Y. S., H. D. Chern, et al. (2002). 'Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.' Hepatology 35(4): 883-9. Hung, C. C., J. J. Tai, et al. (2005). 'Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response.' Pharmacogenomics 6(4): 411-7. Ingelman-Sundberg, M., M. Oscarson, et al. (2001). 'Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles.' Cancer Epidemiol Biomarkers Prev 10(12): 1307-8. Inui, K. I., S. Masuda, et al. (2000). 'Cellular and molecular aspects of drug transport in the kidney.' Kidney Int 58(3): 944-58. Johne, A., K. Kopke, et al. (2002). 'Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.' Clin Pharmacol Ther 72(5): 584-94. Kawajiri, K., H. Eguchi, et al. (1996). 'Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer.' Cancer Res 56(1): 72-6. Kerb, R., A. S. Aynacioglu, et al. (2001). 'The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.' Pharmacogenomics J 1(3): 204-10. Kim, R. B., B. F. Leake, et al. (2001). 'Identification of functionally variant MDR1 alleles among European Americans and African Americans.' Clin Pharmacol Ther 70(2): 189-99. Kimchi-Sarfaty, C., J. M. Oh, et al. (2007). 'A 'silent' polymorphism in the MDR1 gene changes substrate specificity.' Science 315(5811): 525-8. Kiyohara, C., T. Hirohata, et al. (1996). 'The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene.' Jpn J Cancer Res 87(1): 18-24. Kroetz, D. L., C. Pauli-Magnus, et al. (2003). 'Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.' Pharmacogenetics 13(8): 481-94. Kullak-Ublick, G. A., B. Stieger, et al. (2004). 'Enterohepatic bile salt transporters in normal physiology and liver disease.' Gastroenterology 126(1): 322-42. Lai, K. C., W. C. Chen, et al. (2005). 'Glutathione S-transferase M1 gene null genotype and gastric cancer risk in Taiwan.' Hepatogastroenterology 52(66): 1916-9. Lee, Y. L., T. R. Hsiue, et al. (2005). 'The association between glutathione S-transferase P1, M1 polymorphisms and asthma in Taiwanese schoolchildren.' Chest 128(3): 1156-62. Li, D., G. L. Zhang, et al. (2007). 'Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.' J Clin Pharm Ther 32(1): 89-95. Liou, Y. H., C. T. Lin, et al. (2006). 'The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.' J Hum Genet 51(10): 857-63. Liu, K. and S. V. Muse (2005). 'PowerMarker: an integrated analysis environment for genetic marker analysis.' Bioinformatics 21(9): 2128-9. Lo, T.-c. (2003). A case-control study of chronic renal disease on herbalists in Taiwan. Institute of Occupational Medicine and Industrial Hygiene. Taipei, National Taiwan University. Master: 71. Lord, G. M., M. Hollstein, et al. (2004). 'DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy.' Am J Kidney Dis 43(4): e11-7. McLemore, T. L., G. A. Warr, et al. (1977). 'Induction of aryl hydrocarbon hydroxylase in human pulmonary alveolar macrophages and peripheral lymphocytes by cigarette tars.' Cancer Lett 2(3): 161-7. Meissner, K., G. Jedlitschky, et al. (2004). 'Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms.' Pharmacogenetics 14(6): 381-5. Mengs, U. (1987). 'Acute toxicity of aristolochic acid in rodents.' Arch Toxicol 59(5): 328-31. Mengs, U. and C. D. Stotzem (1993). 'Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology.' Arch Toxicol 67(5): 307-11. Mickley, L. A., J. S. Lee, et al. (1998). 'Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors.' Blood 91(5): 1749-56. Mooney, L. A., D. A. Bell, et al. (1997). 'Contribution of genetic and nutritional factors to DNA damage in heavy smokers.' Carcinogenesis 18(3): 503-9. Moore, L. B., B. Goodwin, et al. (2000). 'St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.' Proc Natl Acad Sci U S A 97(13): 7500-2. Nakajima, M., T. Yokoi, et al. (1999). 'Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.' J Biochem (Tokyo) 125(4): 803-8. Nakamura, T., T. Sakaeda, et al. (2002). 'Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.' Clin Pharmacol Ther 71(4): 297-303. Nortier, J. L., M. C. Martinez, et al. (2000). 'Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).' N Engl J Med 342(23): 1686-92. Pfau, W., H. H. Schmeiser, et al. (1990). 'Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA.' Carcinogenesis 11(2): 313-9. Pfohl-Leszkowicz, A., Y. Grosse, et al. (1993). 'Ochratoxin A-related DNA adducts in urinary tract tumours of Bulgarian subjects.' IARC Sci Publ(124): 141-8. Phang, J. M., C. M. Poore, et al. (1993). 'Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells.' Cancer Res 53(24): 5977-81. Puga, A., D. W. Nebert, et al. (1997). 'Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance.' Crit Rev Toxicol 27(2): 199-222. Rintala, S., T. L. Tammela, et al. (1998). 'CYP1A1 activity in renal cell carcinoma and in adjacent normal renal tissue.' Urol Res 26(2): 117-21. Robisch, G., O. Schimmer, et al. (1982). 'Aristolochic acid is a direct mutagen in Salmonella typhimurium.' Mutat Res 105(4): 201-4. Sakaeda, T. (2005). 'MDR1 genotype-related pharmacokinetics: fact or fiction?' Drug Metab Pharmacokinet 20(6): 391-414. Satko, S. G. and B. I. Freedman (2004). 'The importance of family history on the development of renal disease.' Curr Opin Nephrol Hypertens 13(3): 337-41. Schaefer, M., I. Roots, et al. (2006). 'In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms.' Pharmacogenet Genomics 16(12): 855-61. Schmeiser, H. H., B. L. Pool, et al. (1984). 'Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium.' Cancer Lett 23(1): 97-101. Schweikl, H., J. A. Taylor, et al. (1993). 'Expression of CYP1A1 and CYP1A2 genes in human liver.' Pharmacogenetics 3(5): 239-49. Shimada, T., C. L. Hayes, et al. (1996). 'Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.' Cancer Res 56(13): 2979-84. Shimada, T., K. Inoue, et al. (2002). 'Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice.' Carcinogenesis 23(7): 1199-207. Shimada, T., H. Yamazaki, et al. (1994). 'Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.' J Pharmacol Exp Ther 270(1): 414-23. Siddiqui, A., R. Kerb, et al. (2003). 'Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.' N Engl J Med 348(15): 1442-8. Siegsmund, M., U. Brinkmann, et al. (2002). 'Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors.' J Am Soc Nephrol 13(7): 1847-54. Song, P., J. K. Lamba, et al. (2006). 'G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression.' J Clin Pharmacol 46(3): 373-9. Soranzo, N., G. L. Cavalleri, et al. (2004). 'Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.' Genome Res 14(7): 1333-44. Stiborova, M., E. Frei, et al. (1999). 'Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy.' Exp Toxicol Pathol 51(4-5): 421-7. Stiborova, M., E. Frei, et al. (2005). 'Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.' Int J Cancer 113(2): 189-97. Stiborova, M., E. Frei, et al. (2003). 'Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.' Carcinogenesis 24(10): 1695-703. Stiborova, M., E. Frei, et al. (2001). 'Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2.' Chem Res Toxicol 14(8): 1128-37. Stiborova, M., B. Sopko, et al. (2005). 'The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen.' Cancer Lett 229(2): 193-204. Takane, H., D. Kobayashi, et al. (2004). 'Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene.' J Pharmacol Exp Ther 311(3): 1179-87. Tan, E. K., D. K. Chan, et al. (2005). 'Effect of MDR1 haplotype on risk of Parkinson disease.' Arch Neurol 62(3): 460-4. Tanabe, M., I. Ieiri, et al. (2001). 'Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.' J Pharmacol Exp Ther 297(3): 1137-43. Tang, K., S. M. Ngoi, et al. (2002). 'Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations.' Pharmacogenetics 12(6): 437-50. Tatu, C. A., W. H. Orem, et al. (1998). 'The etiology of Balkan endemic nephropathy: still more questions than answers.' Environ Health Perspect 106(11): 689-700. Tsai, P. C., W. Huang, et al. (2006). 'Genetic polymorphisms in CYP1A1 and GSTM1 predispose humans to PCBs/PCDFs-induced skin lesions.' Chemosphere 63(8): 1410-8. Vanherweghem, J. L., D. Abramowicz, et al. (1996). 'Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy.' Am J Kidney Dis 27(2): 209-15. Vanherweghem, J. L., M. Depierreux, et al. (1993). 'Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs.' Lancet 341(8842): 387-91. Vanherweghem, L. J. (1998). 'Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy).' J Altern Complement Med 4(1): 9-13. Wang, B., S. Ngoi, et al. (2006). 'The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines.' Mol Pharmacol 70(1): 267-76. Wang, G., L. Zhang, et al. (2006). 'Genetic polymorphisms of GSTT1, GSTM1, and NQO1 genes and diabetes mellitus risk in Chinese population.' Biochem Biophys Res Commun 341(2): 310-3. Williamson, E. M. (2005). 'Interactions between herbal and conventional medicines.' Expert Opin Drug Saf 4(2): 355-78. Wolf, C. R. (1991). 'Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.' IARC Sci Publ(115): 281-7. Wu, M. T., J. M. Lee, et al. (2002). 'Genetic polymorphisms of cytochrome P4501A1 and oesophageal squamous-cell carcinoma in Taiwan.' Br J Cancer 87(5): 529-32. Wu, Y., Z. Liu, et al. (2005). 'Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy.' Hum Exp Toxicol 24(2): 41-7. Yang, C. S., C. H. Lin, et al. (2000). 'Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs.' Am J Kidney Dis 35(2): 313-8. Yeh, G. C., J. Lopaczynska, et al. (1992). 'A new functional role for P-glycoprotein: efflux pump for benzo(alpha)pyrene in human breast cancer MCF-7 cells.' Cancer Res 52(23): 6692-5. Zhang, W. X., B. Chen, et al. (2007). 'Effect of MDR1 gene polymorphism on progression of end-stage renal disease.' Acta Pharmacol Sin 28(4): 579-83. Zimprich, F., R. Sunder-Plassmann, et al. (2004). 'Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy.' Neurology 63(6): 1087-9. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29728 | - |
| dc.description.abstract | 中草藥腎病變（Chinese herbs nephropathy，CHN）是一種快速進展至腎間質纖維化，因而導致進入末期腎衰竭（end-stage renal disease，ESRD）的疾病，致病原因除了馬兜鈴酸的細胞毒性之外，在此族群中是否也因基因耐受性不同而導致疾病，目前仍是未定論。
本研究經由2000至2007年間回溯性與前瞻性研究方式。在台大醫院篩選出可能為中草藥腎病變的病人共69名，以及曾使用中草藥一個月以上之健康對照組82名，紀錄他們的病史與用藥史。並使用SNPstream與PCR-RFLP方法分析CYP1A1、CYP1A2、NQO1、NAT2、NAT1、GSTM1、GSTT1、GSTP1、CYP2C19與MDR1基因共19個SNP。 結果顯示單一核苷酸多型性如CYP1A2 -3860 GA型、MDR1 2677 GT型與3435 CT型顯著增加疾病風險，校正後勝算比（odds ratio，OR）分別為2.71（CI95% 1.03 – 7.13）、3.94（CI95% 1.19 – 13.05）與3.65（CI95% 1.34 – 9.97）。而在雙體型（haplotype combinations）分析上，CYP1A1*2A/2B與MDR1 2677/3435的GC/TT型均達顯著水準，OR分別為7.76（CI95% 1.32 – 45.45）與4.82（CI95% 1.39 – 16.73）。另外結合MDR1 C3435T與CYP1A1單體型（haplotype）發現，同時攜帶MDR1 exon 26 3435位置的CT或TT型與CYP1A1的突變型（*2A或*2B），會大幅增加OR為13.33（CI95% 1.39 – 128.23，p = 0.03）。顯示兩個基因對於疾病可能有協同效應（synergistic effect）。 本研究顯示CYP1A1/2與MDR1的突變可能會影響中草藥腎病變的致病，並且可能有協同效應。因此未來可能需要更多的研究樣本以決定篩檢CYP1A1/2與MDR1是否可以有助於預測中草藥腎病變的風險。 | zh_TW |
| dc.description.abstract | Chinese herbs nephropathy (CHN) is characterized by progressive renal interstitial fibrosis followed by end-stage renal disease. It is known to be caused by the cellular toxicity of aristolochic acid. However, the association between genetic polymorphisms and complex diseases such as CHN has not been confirmed. Sixty-nine patients with a probability of CHN were found by a retrospective and a prospective study at National Taiwan University Hospital during 2000-2007. Eighty-two individuals with herbal-use for more than one month and normal renal function were recruited as controls. The 19 single nucleotide polymorphisms in CYP1A1, CYP1A2, NQO1, NAT2, NAT1, GSTM1, GSTT1, GSTP1, CYP2C19, and MDR1 were determined by SNPstream® and PCR-RFLP method.
Our study showed that the CYP1A2 -3860 GA type, MDR1 2677 GT type, and 3435 CT type were significantly correlated with the risk of CHN with adjusted odds ratios (OR) of 2.71 (CI95% 1.03 - 7.13) , 3.94 (CI95% 1.19 - 13.05), and 3.65(CI95% 1.34 - 9.97), respectively. The analysis of haplotype combinations revealed an adjusted OR 7.76 (CI95% 1.32 - 45.45), and 4.82 (CI95% 1.39 - 16.73) for CYP1A1*2A/2B, and MDR1 2677/3435 GC/TT type in CHN. In addition, simultaneous mutation of MDR1 C3435T and CYP1A1 had an adjusted OR of 13.33 (CI95% 1.39 - 128.23). Our result showed that single nucleotide polymorphisms of CYP1A1/2 and MDR1 might be associated with CHN, and they might have synergy effect. Further study in more patients may be required to determine if CYP1A1/2 and MDR1 mutation screening is helpful in predicting risk of CHN. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T01:16:28Z (GMT). No. of bitstreams: 1 ntu-96-R94423020-1.pdf: 5875556 bytes, checksum: c14fe188d7d9652c3828fcbaa3c1675b (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | 中文摘要 I
ABSTRACT II 目錄 III 表目錄 V 圖目錄 VI 中英對照表 VII 第一章 前言 1 第二章 文獻回顧 4 2.1 中草藥腎病變的組織型態與描述流行病學 4 2.1.1 病理組織型態與疾病進程 4 2.1.2 疾病流行病學描述 4 2.1.3 致病機制探討 5 2.2 潛在危險因子研究 6 2.2.1 馬兜鈴酸 6 2.2.2 中草藥 9 2.2.3 家族史基因 9 2.2.4 職業 9 2.3 基因多型性的影響 10 2.3.1 CYP1A1與CYP1A2的回顧 13 2.3.2 MDR1的回顧 14 2.4 研究目的 16 第三章 材料與方法 17 3.1. 試驗設計流程 18 3.1.1. 研究族群與檢體採集 18 3.1.2. 問卷設計與資料收集 19 3.1.3. 去氧核糖核酸檢體萃取 19 3.2. 基因型鑑定 20 3.2.1. 聚合酵素鏈鎖限制酶反應（PCR-RFLP） 20 3.2.2. SNPstream測定 31 3.2.3. 基因型定義 33 3.2.4. 統計分析 34 第四章 研究結果 36 4.1. 基本族群人口學特徵 36 4.2. 中草藥使用目的分析 38 4.3. 基因型鑑定 38 4.4. 基因疾病相關性研究 39 4.5. 單體型（HAPLOTYPE）與雙體型（HAPLOTYPE COMBINATIONS）疾病 相關性研究 43 4.6. 累積突變與疾病風險研究 46 第五章 討論 48 5.1 基因結果探討與結論 48 5.2 研究限制 52 第六章 結論與建議 53 參考文獻 54 附錄一 實驗材料與儀器表 64 附錄二 受試者同意書 67 附錄三 問卷 72 | |
| dc.language.iso | zh-TW | |
| dc.title | 台灣地區中草藥腎病變與CYP1A1/2、MDR1基因多型性之病例對照研究 | zh_TW |
| dc.title | Effect of CYP1A1/2 and MDR1 polymorphisms on the risk of Chinese herb nephropathy in Taiwan - a case-control study | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 95-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 吳寬墩(Kwan-Dun Wu) | |
| dc.contributor.oralexamcommittee | 黃金鼎(Jin-Ding Huang),沈麗娟(Li-Jiuan Shen) | |
| dc.subject.keyword | 腎臟疾病,中草藥,馬兜鈴酸,基因多型性,MDR1基因,細胞色素P450酵素系統, | zh_TW |
| dc.subject.keyword | kidney diseases,drugs, Chinese herbal,aristolochic acids,polymorphism, genetic,cytochrome P-450 enzyme system,genes, MDR, | en |
| dc.relation.page | 79 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2007-07-19 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥學研究所 | zh_TW |
| 顯示於系所單位： | 藥學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 目前未授權公開取用 | 5.74 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。